UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event
Virtual-Strategy,
Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival…